Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Jiangsu Hansoh Pharmaceutical Co., Ltd.

ClinicalTrials.gov lists Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor of 134 trials. It has 174 active development programs and 27 approved assets.

CN Industry
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

30 0 2011 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 25 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 30 in 2026 and about 23 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Logo Hansoh Pharmaceutical, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers Jiangsu Hansoh Pharmaceutical Co., Ltd.: 134 lead-sponsored trials and 0 legal-entity registrations.

Get the Jiangsu Hansoh Pharmaceutical Co., Ltd. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (57)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Lung Neoplasms 28
Carcinoma, Non-Small-Cell Lung 23
Diabetes Mellitus 12
Diabetes Mellitus, Type 2 12
Anemia 6

Trials by start year as sponsor or collaborator (16)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 25
2025 18
2024 16
2023 16
2022 13
2021 20
2020 9
2019 5
2018 1
2017 2

Prediction, not a registry value: median of 27 months from start to primary completion across 23 trials still running at the 2026-10-09 snapshot; 7 of 23 predicted trials reach the 36-month horizon; registered median of 16 months across 32 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (174)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Adebrelimab Carcinoma, Non-Small-Cell Lung Phase 3 3
HS-10504 Lung Neoplasms Phase 3 3
HS-10370 Carcinoma, Non-Small-Cell Lung Phase 3 3
HS-10370 Lung Neoplasms Phase 3 3
Adebrelimab Lung Neoplasms Phase 3 3

Approved assets (27)

Shown in this order: max phase first.

Approved assets
Drug Trials
morinidazole 2
Flumatinib 1
Tenofovir Amibufenamide(TMF) 1
Flumatinib mesylate tablets (400mg) 1
Imatinib 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
67% hit target (n=12) 57% on time (n=14)

Journals published in (47)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 4
The Lancet. Oncology 4
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 3
The New England journal of medicine 3
British journal of cancer 2

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
Jiangsu Hansoh Pharmaceutical Co. Ltd. Lianyungang, CN Health Canada

Organization relationships (5)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Co sponsors trial with 2
Chinese Academy of Medical Sciences & Peking Union Medical College Co sponsors trial with 1
Chinese PLA General Hospital Co sponsors trial with 1
First Affiliated Hospital of Dalian Medical University Co sponsors trial with 1
GeneCast Biotechnology Co., Ltd. Co sponsors trial with 1

Latest dated events (150)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-22 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-17 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (411)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABL1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
BCR Trial sponsor Named in trial inclusion criteria
BCR Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.